The Centers for Disease Control and Prevention said on Friday that MRNA from Moderna Inc.,
The COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency’s findings about the coronavirus vaccine developed by BioNTech SE BNTX,
and Pfizer Inc. PFE,
Moderna’s shares rose 1.6% in pre-market trading on Monday. There have been 10 cases of anaphylaxis among the approximately 4 million doses administered between December 21 and January 10, according to the CDC report. Both vaccines are based on mRNA, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC previously recommended that health professionals prepare for the possibility of anaphylaxis among some people who are vaccinated. Moderna shares have soared 520.3% in the last 12 months, while the S&P 500 SPX
increased by 15.6%.
